[go: up one dir, main page]

ATE525070T1 - Silbininkomponente zur behandlung von hepatitis - Google Patents

Silbininkomponente zur behandlung von hepatitis

Info

Publication number
ATE525070T1
ATE525070T1 AT08849759T AT08849759T ATE525070T1 AT E525070 T1 ATE525070 T1 AT E525070T1 AT 08849759 T AT08849759 T AT 08849759T AT 08849759 T AT08849759 T AT 08849759T AT E525070 T1 ATE525070 T1 AT E525070T1
Authority
AT
Austria
Prior art keywords
hepatitis
treatment
silbine
incomponent
ribavirin
Prior art date
Application number
AT08849759T
Other languages
English (en)
Inventor
Lucio Rovati
Amato Massimo D
Ulrich Mengs
Ralf-Torsten Pohl
Peter Ferenci
Original Assignee
Madaus Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus Gmbh filed Critical Madaus Gmbh
Application granted granted Critical
Publication of ATE525070T1 publication Critical patent/ATE525070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08849759T 2007-11-15 2008-11-14 Silbininkomponente zur behandlung von hepatitis ATE525070T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98816807P 2007-11-15 2007-11-15
EP07022187 2007-11-15
EP08005459 2008-03-25
PCT/EP2008/009659 WO2009062737A1 (en) 2007-11-15 2008-11-14 Silibinin component for the treatment of hepatitis

Publications (1)

Publication Number Publication Date
ATE525070T1 true ATE525070T1 (de) 2011-10-15

Family

ID=40259958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08849759T ATE525070T1 (de) 2007-11-15 2008-11-14 Silbininkomponente zur behandlung von hepatitis

Country Status (15)

Country Link
US (2) US20110182858A1 (de)
EP (2) EP2219642B1 (de)
JP (1) JP5349486B2 (de)
KR (1) KR101435242B1 (de)
CN (1) CN102300570B (de)
AT (1) ATE525070T1 (de)
AU (1) AU2008323156B2 (de)
CA (1) CA2703834C (de)
DK (1) DK2219642T3 (de)
ES (2) ES2374117T3 (de)
HK (1) HK1142270A1 (de)
MX (1) MX2010005107A (de)
PL (2) PL2219642T3 (de)
PT (1) PT2219642E (de)
WO (1) WO2009062737A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2761656C (en) * 2009-05-14 2017-02-07 Lucio Claudio Rovati Amorphous silibinin for the treatment of viral hepatitis
WO2011051742A1 (en) * 2009-10-28 2011-05-05 Modutech S.A. Preparation comprising amino acids and plants and its activity in the alcohol detoxification
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20160324795A1 (en) * 2014-01-27 2016-11-10 Kaohsiung Medical University Silibinin nanoparticle and a method of treating hepatitis c thereof
CN106170877B (zh) * 2014-02-26 2018-08-31 联邦科学和工业研究组织 形成钙钛矿光敏装置的光敏层的方法
PL3203989T3 (pl) 2014-10-09 2020-06-29 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostrukturalne preparaty do dostarczania sylibininy i innych składników czynnych do leczenia chorób oczu
US20180280343A1 (en) * 2015-10-02 2018-10-04 Theresa PACHECO Topical silibinin formulations and uses therefor
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
CN111841501A (zh) * 2020-06-23 2020-10-30 五邑大学 一种治疗炎症性疾病的药物组合物及其应用
WO2023008981A1 (ko) * 2021-07-30 2023-02-02 경희대학교 산학협력단 항바이러스 조성물 및 이의 이용
CN117269374B (zh) * 2023-11-22 2024-01-16 汤臣倍健股份有限公司 一种水飞蓟提取物中人为掺假的鉴别方法
CN117919256B (zh) * 2024-03-25 2024-05-24 潍坊众邦制药有限公司 一种含有药用甾醇活性物质组合物在制备治疗肝炎的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061765A (en) * 1973-01-19 1977-12-06 Dr. Madaus & Co. Polyhydroxyphenylchromanone salts and therapeutic composition
DE3537656A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus GmbH & Co, 5000 Köln Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin
DE3442639A1 (de) * 1984-11-22 1986-05-22 Dr. Madaus & Co, 5000 Köln Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
IT1241673B (it) 1989-10-09 1994-01-27 Istituto Biochimico Italiano Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono.
DE4401902C2 (de) * 1994-01-24 2000-02-03 Madaus Ag Verwendung von Flavolignanen als Adjuvans in der Tumortherapie
WO1999043336A1 (en) * 1998-02-27 1999-09-02 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
US6262019B1 (en) * 1998-04-30 2001-07-17 Vit-Immune, L. C. Method of treatment of glutathione deficient mammals
KR20010101074A (ko) * 1998-11-24 2001-11-14 추후제출 17-케토스테로이드 화합물 및 그의 유도체, 대사산물 및전구체의 간염 ｃ 바이러스 및 기타 토가바이러스 치료용용도
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
US6699900B2 (en) 2001-04-07 2004-03-02 Jan E. Zielinski Hydrophilic and lipophilic silibinin pro-forms
CN100451501C (zh) 2003-08-26 2009-01-14 株式会社东芝 冰箱
US7078064B2 (en) * 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
CN1762345A (zh) 2005-09-29 2006-04-26 丛晓东 一种水飞蓟宾注射剂及其制备方法
CN100389767C (zh) * 2005-09-30 2008-05-28 天津药物研究院 一种含活性成分水飞蓟宾及其盐经注射给药的稳定的药物组合物
CN100534992C (zh) * 2005-12-26 2009-09-02 浙江海正药业股份有限公司 水飞蓟宾酯类衍生物及其制备方法和制备药物的用途
CN101244059B (zh) 2008-03-31 2010-11-17 广州佳科生物科技有限公司 一种复方水飞蓟宾注射剂及其制备方法和应用
CN101439018A (zh) 2008-11-11 2009-05-27 扬子江药业集团四川海蓉药业有限公司 一种静脉注射用水飞蓟宾类化合物乳剂及其制备方法

Also Published As

Publication number Publication date
ES2374117T3 (es) 2012-02-13
CA2703834C (en) 2014-05-20
AU2008323156B2 (en) 2012-05-31
MX2010005107A (es) 2010-05-27
US20130236420A1 (en) 2013-09-12
PT2219642E (pt) 2011-10-18
DK2219642T3 (da) 2011-12-05
CN102300570B (zh) 2015-01-14
PL2219642T3 (pl) 2012-02-29
US20110182858A1 (en) 2011-07-28
US9248115B2 (en) 2016-02-02
EP2392326B9 (de) 2018-09-05
AU2008323156A1 (en) 2009-05-22
KR20100094981A (ko) 2010-08-27
WO2009062737A1 (en) 2009-05-22
KR101435242B1 (ko) 2014-08-29
PL2392326T3 (pl) 2018-07-31
JP2011503133A (ja) 2011-01-27
ES2662700T3 (es) 2018-04-09
EP2392326B1 (de) 2018-01-24
EP2219642A1 (de) 2010-08-25
HK1142270A1 (en) 2010-12-03
ES2662700T9 (es) 2018-08-27
CN102300570A (zh) 2011-12-28
EP2219642B1 (de) 2011-09-21
EP2392326A1 (de) 2011-12-07
JP5349486B2 (ja) 2013-11-20
CA2703834A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
CY1112259T1 (el) Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
EP1951319A4 (de) Zur behandlung von krebserkrankungen beim menschen geeigneter chimärer immunrezeptor
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP2056848A4 (de) Verwendung von extrakten zur behandlung viraler erkrankungen
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
RS53911B1 (en) TREATMENT IN HEPATITIS B VIRUS INFECTION ONLY OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND THE DISEASES OF THE LIVER
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
ATE548044T1 (de) Kombinationstherapie zur behandlung von hiv- infektionen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE382383T1 (de) Apherese-vorrichtung
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2219642

Country of ref document: EP